Rhelion ships PEX010 for Phase 3 microdose psilocybin trial
Filament delivered PEX010 to Bruyère Health Research Institute for a Phase 3, placebo-controlled microdose psilocybin trial in palliative care across seven Canadian sites.
Material DetailsContext by AI AnalystThis extends Rhelion/Filament’s strategy as a key psilocybin supplier…